981 results on '"Schrier, R."'
Search Results
2. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
- Author
-
Adler, A, Agodoa, L, Algra, A, Asselbergs, F W, Beckett, N, Berge, E, Black, H, Brouwers, F P J, Brown, M, Bulpitt, C J, Byington, B, Chalmers, J, Cushman, W C, Cutler, J, Davis, B R, Devereaux, R B, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A K, Holman, R R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S E, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L H, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, M H, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C J, Pfeffer, M, Poulter, N R, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J A, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W H, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z Y, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J, Copland, Emma, Canoy, Dexter, Nazarzadeh, Milad, Bidel, Zeinab, Ramakrishnan, Rema, Woodward, Mark, Chalmers, John, Teo, Koon K, Pepine, Carl J, Davis, Barry R, Kjeldsen, Sverre, Sundström, Johan, and Rahimi, Kazem
- Published
- 2021
- Full Text
- View/download PDF
3. Predictors of attrition in a cohort study of HIV infection and methamphetamine dependence
- Author
-
Cattie, J, Marquine, MJ, Bolden, KA, Obermeit, LC, Morgan, EE, Franklin, DR, Umlauf, A, Beck, JM, Hampton Atkinson, J, Woods, SP, Grant, I, Ellis, RJ, Achim, C, Letendre, S, Schrier, R, Heaton, RK, Atkinson, JH, Cherner, M, Marcotte, T, Brown, G, Jernigan, T, Dale, A, Liu, T, Scadeng, M, Fennema-Notestine, C, Archibald, SL, Masliah, E, Lipton, S, Marquie, J, Gamst, AC, Cushman, C, Abramson, I, Vaida, F, Deutsch, R, Minassian, A, Perry, W, Geyer, M, Henry, B, Grethe, AB, Paulus, M, Morris, S, Smith, DM, Semenova, S, Markou, A, and Kaul, M
- Subjects
Nursing ,Public Health and Health Services ,Psychology ,Substance Abuse - Abstract
Longitudinal cohort studies of HIV and substance use disorders play an important role in understanding these conditions, but high rates of attrition can threaten their integrity and generalizability. This study aimed to identify factors associated with attrition in a 5-year observational cohort study of 469 individuals with and without HIV infection and methamphetamine (MA) dependence. Rates of attrition in our four study groups were approximately 24% in HIV-MA-, 15% in HIV+MA-, 56% in HIV-MA+, and 47% in HIV+MA+ individuals. Predictors of attrition in the overall cohort included history of MA, alcohol, and other substance dependence, learning impairment, reduced cognitive reserve, and independence in activities of daily living (all ps < 0.05), but varied somewhat by clinical group. Of particular note, enrollment in a neuroimaging sub-study was associated with significantly boosted rates of retention in the MA groups. Results from this investigation highlight the complexity of the clinical factors that influence retention in cohort studies of HIV-infected MA users and might guide the development and implementation of targeted retention efforts.
- Published
- 2015
4. Shallow Encoding and Forgetting Are Associated with Dependence in Instrumental Activities of Daily Living Among Older Adults Living with HIV Infection
- Author
-
Fazeli, PL, Doyle, KL, Scott, JC, Iudicello, JE, Casaletto, KB, Weber, E, Moore, DJ, Morgan, EE, Grant, I, Woods, SP, Hampton Atkinson, J, Ellis, RJ, Allen McCutchan, J, Marcotte, TD, Marquie-Beck, J, Sherman, M, Letendre, S, Capparelli, E, Schrier, R, Rosario, D, LeBlanc, S, Heaton, RK, Cherner, M, Dawson, M, Jernigan, T, Fennema-Notestine, C, Archibald, SL, Hesselink, J, Annese, J, Taylor, MJ, Masliah, E, Achim, C, Everall, I, Richman, D, Smith, DM, Lipton, S, Gamst, AC, Cushman, C, Abramson, I, Vaida, F, Deutsch, R, and Umlauf, A
- Subjects
Psychology ,Clinical and Health Psychology ,Applied and Developmental Psychology ,Rehabilitation ,HIV/AIDS ,Neurodegenerative ,Behavioral and Social Science ,Acquired Cognitive Impairment ,Brain Disorders ,Clinical Research ,Infectious Diseases ,Sexually Transmitted Infections ,Neurosciences ,Aging ,Infection ,Activities of Daily Living ,Adult ,Aged ,Cohort Studies ,Disabled Persons ,Female ,HIV Infections ,Humans ,Male ,Memory Disorders ,Middle Aged ,Neuropsychological Tests ,Surveys and Questionnaires ,Verbal Learning ,Disability ,Everyday functioning ,Learning and memory ,HIV Neurobehavioral Research Program (HNRP) Group ,Cognitive Sciences ,Clinical Psychology ,Applied and developmental psychology ,Biological psychology ,Clinical and health psychology - Abstract
Aging and HIV are both risk factors for memory deficits and declines in real-world functioning. However, we know little about the profile of memory deficits driving instrumental activities of daily living (IADL) declines across the lifespan in HIV. This study examined 145 younger (
- Published
- 2014
5. Differential role of nitric oxide in the psychedelic symptoms induced by racemic ketamine and esketamine in human volunteers
- Author
-
Jonkman, K., van der Schrier, R., van Velzen, M., Aarts, L., Olofsen, E., Sarton, E., Niesters, M., and Dahan, A.
- Published
- 2018
- Full Text
- View/download PDF
6. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers
- Author
-
van der Schrier, R., Jonkman, K., van Velzen, M., Olofsen, E., Drewes, A M, Dahan, A., and Niesters, M.
- Published
- 2017
- Full Text
- View/download PDF
7. Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression
- Author
-
Algera, H., Schrier, R. van der, Cavalla, D., Velzen, M. van, Roozekrans, M., McMorn, A., Snape, M., Horrigan, J.P., Evans, S., Kiernan, B., Sarton, E., Olofsen, E., Niesters, M., and Dahan, A.
- Subjects
Male ,Thiazepines ,Respiratory System Agents ,Antidepressive Agents, Tricyclic ,Carbon Dioxide ,Analgesics, Opioid ,Remifentanil ,Anesthesiology and Pain Medicine ,Double-Blind Method ,Humans ,Female ,Alfentanil ,Respiratory Insufficiency ,alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid - Abstract
Background Animal data suggest that the antidepressant and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor modulator tianeptine is able to prevent opioid-induced respiratory depression. The hypothesis was that oral or intravenous tianeptine can effectively prevent or counteract opioid-induced respiratory depression in humans. Methods Healthy male and female volunteers participated in two studies that had a randomized, double blind, placebo-controlled, crossover design. First, oral tianeptine (37.5-, 50-, and 100-mg doses with 8 subjects) pretreatment followed by induction of alfentanil-induced respiratory depression (alfentanil target concentration, 100 ng/ml) was tested. Primary endpoint was ventilation at an extrapolated end-tidal carbon dioxide concentration of 55 mmHg (V̇E55). Next, the ability of four subsequent and increasing infusions of intravenous tianeptine (target tianeptine plasma concentrations 400, 1,000, 1,500, and 2,000 ng/ml, each given over 15 min) to counteract remifentanil-induced respiratory depression was determined in 15 volunteers. Ventilation was measured at isohypercpania (baseline ventilation 20 ± 2 l/min). The primary endpoint was minute ventilation during the 60 min of tianeptine versus placebo infusion. Results Alfentanil reduced V̇E55 to 13.7 (95% CI, 8.6 to 18.8) l/min after placebo pretreatment and to 17.9 (10.2 to 25.7) l/min after 50-mg tianeptine pretreatment (mean difference between treatments 4.2 (–11.5 to 3.0) l/min, P = 0.070). Intravenous tianeptine in the measured concentration range of 500 to 2,000 ng/ml did not stimulate ventilation but instead worsened remifentanil-induced respiratory depression: tianeptine, 9.6 ± 0.8 l/min versus placebo 15.0 ± 0.9 l/min; mean difference, 5.3 l/min; 95% CI, 2.5 to 8.2 l/min; P = 0.001, after 1 h of treatment. Conclusions Neither oral nor intravenous tianeptine were respiratory stimulants. Intravenous tianeptine over the concentration range of 500 to 2000 ng/ml worsened respiratory depression induced by remifentanil. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
- Published
- 2022
8. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
- Author
-
Nazarzadeh, Milad, primary, Bidel, Zeinab, additional, Canoy, Dexter, additional, Copland, Emma, additional, Bennett, Derrick A, additional, Dehghan, Abbas, additional, Davey Smith, George, additional, Holman, Rury R, additional, Woodward, Mark, additional, Gupta, Ajay, additional, Adler, Amanda I, additional, Wamil, Malgorzata, additional, Sattar, Naveed, additional, Cushman, William C, additional, McManus, Richard J, additional, Teo, Koon, additional, Davis, Barry R, additional, Chalmers, John, additional, Pepine, Carl J, additional, Rahimi, Kazem, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Cutler, J, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
- Author
-
Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., Teo K. K., Rahimi, K, Bidel, Z, Nazarzadeh, M, Copland, E, Canoy, D, Wamil, M, Majert, J, Mcmanus, R, Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Boersma, E, Brouwers, F, Brown, M, Brugts, J, Bulpitt, C, Byington, R, Cushman, W, Cutler, J, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Chalmers, J, Davis, B, Pepine, C, Teo, K, Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Wamil M., Majert J., McManus R., Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Boersma E., Brouwers F. P. J., Brown M., Brugts J. J., Bulpitt C. J., Byington R. P., Cushman W. C., Cutler J., Devereaux R. B., Dwyer J. P., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Chalmers J., Davis B. R., Pepine C. J., and Teo K. K.
- Abstract
Background: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. Methods: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission. Findings: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59–75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55–64 years, 128 506 (35·8%) 65–74 years, 54 016 (15·1%) 75–84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg
- Published
- 2021
10. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
- Author
-
Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., Wang J., Adler, A, Agodoa, L, Algra, A, Asselbergs, F, Beckett, N, Berge, E, Black, H, Brouwers, F, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Cushman, W, Cutler, J, Davis, B, Devereaux, R, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, A, Holman, R, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, S, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, L, Lueders, S, Macmahon, S, Mancia, G, Matsuzaki, M, Mehlum, M, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Pitt, B, Poulter, N, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, W, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, Z, Anderson, C, Baigent, C, Brenner, B, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundstrom, J, Turnbull, F, Viberti, G, Wang, J, Adler A., Agodoa L., Algra A., Asselbergs F. W., Beckett N. S., Berge E., Black H., Brouwers F. P. J., Brown M., Bulpitt C. J., Byington R. P., Chalmers J., Cushman W. C., Cutler J., Davis B. R., Devereaux R. B., Dwyer J., Estacio R., Fagard R., Fox K., Fukui T., Gupta A. K., Holman R. R., Imai Y., Ishii M., Julius S., Kanno Y., Kjeldsen S. E., Kostis J., Kuramoto K., Lanke J., Lewis E., Lewis J. B., Lievre M., Lindholm L. H., Lueders S., MacMahon S., Mancia G., Matsuzaki M., Mehlum M. H., Nissen S., Ogawa H., Ogihara T., Ohkubo T., Palmer C. R., Patel A., Pepine C. J., Pfeffer M. A., Pitt B., Poulter N. R., Rakugi H., Reboldi G., Reid C., Remuzzi G., Ruggenenti P., Saruta T., Schrader J., Schrier R., Sever P., Sleight P., Staessen J. A., Suzuki H., Thijs L., Ueshima K., Umemoto S., van Gilst W. H., Verdecchia P., Wachtell K., Whelton P., Wing L., Woodward M., Yui Y., Yusuf S., Zanchetti A., Zhang Z. -Y., Anderson C., Baigent C., Brenner B. M., Collins R., de Zeeuw D., Lubsen J., Malacco E., Neal B., Perkovic V., Rodgers A., Rothwell P., Salimi-Khorshidi G., Sundstrom J., Turnbull F., Viberti G., and Wang J.
- Abstract
Background: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure. Methods: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat. Findings: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/8
- Published
- 2021
11. Sepsis and Acute Renal Failure
- Author
-
Schrier, R. W., Zolty, E., Wang, W., and Vincent, Jean-Louis, editor
- Published
- 2006
- Full Text
- View/download PDF
12. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity
- Author
-
Schrier, R. van der, Dahan, J.D.C., Boon, M., Sarton, E., Velzen, M. van, Niesters, M., and Dahan, A.
- Subjects
Analgesics, Opioid ,Anesthesiology and Pain Medicine ,Naloxone ,Narcotic Antagonists ,Respiratory System Agents ,Humans ,Respiratory Insufficiency - Abstract
Opioids may produce life-threatening respiratory depression and death from their actions at the opioid receptors within the brainstem respiratory neuronal network. Since there is an increasing number of conditions where the administration of the opioid receptor antagonist naloxone is inadequate or undesired, there is an increased interest in the development of novel reversal and prevention strategies aimed at providing efficacy close to that of the opioid receptor antagonist naloxone but with fewer of its drawbacks such as its short duration of action and lesser ability to reverse high-affinity opioids, such as carfentanil, or drug combinations. To give an overview of this highly relevant topic, the authors systematically discuss predominantly experimental pharmacotherapies, published in the last 5 yr, aimed at reversal of opioid-induced respiratory depression as alternatives to naloxone. The respiratory stimulants are discussed based on their characteristics and mechanism of action: nonopioid controlled substances (e.g., amphetamine, cannabinoids, ketamine), hormones (thyrotropin releasing hormone, oxytocin), nicotinic acetylcholine receptor agonists, ampakines, serotonin receptor agonists, antioxidants, miscellaneous peptides, potassium channel blockers acting at the carotid bodies (doxapram, ENA001), sequestration techniques (scrubber molecules, immunopharmacotherapy), and opioids (partial agonists/antagonists). The authors argue that none of these often still experimental therapies are sufficiently tested with respect to efficacy and safety, and many of the agents presented have a lesser efficacy at deeper levels of respiratory depression, i.e., inability to overcome apnea, or have ample side effects. The authors suggest development of reversal strategies that combine respiratory stimulants with naloxone. Furthermore, they encourage collaborations between research groups to expedite development of viable reversal strategies of potent synthetic opioid-induced respiratory depression.
- Published
- 2022
13. Recent Advances in the Understanding of Water Metabolism in Heart Failure
- Author
-
Schrier, R. W., Martin, P. Y., Zingg, Hans H., editor, Bourque, Charles W., editor, and Bichet, Daniel G., editor
- Published
- 1998
- Full Text
- View/download PDF
14. Bilateral Kidney Disease and Hypertension
- Author
-
Malhotra, D., Schrier, R. W., Lüscher, Thomas F., editor, and Kaplan, Norman Meyer, editor
- Published
- 1992
- Full Text
- View/download PDF
15. Strategies in Management of Acute Renal Failure in the Intensive Therapy Unit
- Author
-
Schrier, R. W., Abraham, W. T., Hensen, J., Bihari, David, editor, and Neild, Guy, editor
- Published
- 1990
- Full Text
- View/download PDF
16. Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers
- Author
-
Roozekrans, M, Olofsen, E, van der Schrier, R, van Gerven, J, Peng, S, McLeod, J, and Dahan, A
- Published
- 2015
- Full Text
- View/download PDF
17. Cytomegalovirus Infects Human Lymphocytes and Monocytes: Virus Expression is Restricted to Immediate-Early Gene Products
- Author
-
Rice, G. P. A., Schrier, R. D., and Oldstone, M. B. A.
- Published
- 1984
18. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
- Author
-
Copland, Emma, primary, Canoy, Dexter, additional, Nazarzadeh, Milad, additional, Bidel, Zeinab, additional, Ramakrishnan, Rema, additional, Woodward, Mark, additional, Chalmers, John, additional, Teo, Koon K, additional, Pepine, Carl J, additional, Davis, Barry R, additional, Kjeldsen, Sverre, additional, Sundström, Johan, additional, Rahimi, Kazem, additional, Adler, A, additional, Agodoa, L, additional, Algra, A, additional, Asselbergs, F W, additional, Beckett, N, additional, Berge, E, additional, Black, H, additional, Brouwers, F P J, additional, Brown, M, additional, Bulpitt, C J, additional, Byington, B, additional, Chalmers, J, additional, Cushman, W C, additional, Cutler, J, additional, Davis, B R, additional, Devereaux, R B, additional, Dwyer, J, additional, Estacio, R, additional, Fagard, R, additional, Fox, K, additional, Fukui, T, additional, Gupta, A K, additional, Holman, R R, additional, Imai, Y, additional, Ishii, M, additional, Julius, S, additional, Kanno, Y, additional, Kjeldsen, S E, additional, Kostis, J, additional, Kuramoto, K, additional, Lanke, J, additional, Lewis, E, additional, Lewis, J, additional, Lievre, M, additional, Lindholm, L H, additional, Lueders, S, additional, MacMahon, S, additional, Mancia, G, additional, Matsuzaki, M, additional, Mehlum, M H, additional, Nissen, S, additional, Ogawa, H, additional, Ogihara, T, additional, Ohkubo, T, additional, Palmer, C, additional, Patel, A, additional, Pepine, C J, additional, Pfeffer, M, additional, Poulter, N R, additional, Rakugi, H, additional, Reboldi, G, additional, Reid, C, additional, Remuzzi, G, additional, Ruggenenti, P, additional, Saruta, T, additional, Schrader, J, additional, Schrier, R, additional, Sever, P, additional, Sleight, P, additional, Staessen, J A, additional, Suzuki, H, additional, Thijs, L, additional, Ueshima, K, additional, Umemoto, S, additional, van Gilst, W H, additional, Verdecchia, P, additional, Wachtell, K, additional, Whelton, P, additional, Wing, L, additional, Woodward, M, additional, Yui, Y, additional, Yusuf, S, additional, Zanchetti, A, additional, Zhang, Z Y, additional, Anderson, C, additional, Baigent, C, additional, Brenner, BM, additional, Collins, R, additional, de Zeeuw, D, additional, Lubsen, J, additional, Malacco, E, additional, Neal, B, additional, Perkovic, V, additional, Pitt, B, additional, Rodgers, A, additional, Rothwell, P, additional, Salimi-Khorshidi, G, additional, Sundström, J, additional, Turnbull, F, additional, Viberti, G, additional, and Wang, J, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Molecular mechanisms of clinical concentrating and diluting disorders
- Author
-
SCHRIER, R, primary
- Published
- 2008
- Full Text
- View/download PDF
20. Dilemmas in Human and Rat Pregnancy: Proposed Mechanisms Relating to Arterial Vasodilation
- Author
-
Schrier, R. W. and Ohara, M.
- Published
- 2010
- Full Text
- View/download PDF
21. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial
- Author
-
Schrier, R. W., Estacio, R. O., and Jeffers, B.
- Published
- 1996
- Full Text
- View/download PDF
22. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study
- Author
-
THULUVATH, P. J., MAHESHWARI, A., WONG, F., YOO, H. W., SCHRIER, R. W., PARIKH, C., STEARE, S., and KORULA, J.
- Published
- 2006
23. Impaired fibrinolytic activity in type II diabetes: Correlation with urinary albumin excretion and progression of renal disease
- Author
-
Kamgar, M, Nobakhthaghighi, N, Shamshirsaz, A A, Estacio, R O, McFann, K K, and Schrier, R W
- Published
- 2006
24. The Safety of Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis and Incidence of Immune Recovery Uveitis Following Potent Antiretroviral Therapy
- Author
-
Wohl, D. A., Kendall, M. A., Owens, S., Holland, G., Nokta, M., Spector, S. A., Schrier, R., Fiscus, S., Davis, M., Jacobson, M. A., Currier, J. S., Squires, K., Alston-Smith, B., Andersen, J., Freeman, W. R., Higgins, M., and Torriani, F. J.
- Published
- 2005
25. Benefit versus Severe Side Effects of Opioid Analgesia Novel Utility Functions of Probability of Analgesia and Respiratory Depression
- Author
-
Roozekrans, M., Schrier, R. van der, Aarts, L., Sarton, E., Velzen, M. van, Niesters, M., Dahan, A., and Olofsen, E.
- Published
- 2018
26. SMOKING: A RISK FACTOR FOR NEPHROPATHY IN NON-INSULIN DEPENDENT DIABETICS
- Author
-
Mehler, P S, Jeffers, B W, Biggerstaff, S L, and Schrier, R W
- Published
- 1998
27. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials
- Author
-
Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., Woodward M., Agodoa, L, Estacio, R, Schrier, R, Lubsen, J, Chalmers, J, Cutler, J, Davis, B, Wing, L, Poulter, N, Sever, P, Remuzzi, G, Ruggenenti, P, Nissen, S, Lindholm, L, Fukui, T, Ogihara, T, Saruta, T, Black, H, Sleight, P, Lievre, M, Suzuki, H, Fox, K, Lisheng, L, Ohkubo, T, Imai, Y, Yusuf, S, Bulpitt, C, Lewis, E, Brown, M, Palmer, C, Wang, J, Pepine, C, Ishii, M, Yui, Y, Kuramoto, K, Pfeff Er, M, Asselbergs, F, Van Gilst, W, Byington, B, Pitt, B, Brenner, B, Remme, W, De Zeeuw, D, Rahman, M, Viberti, G, Teo, K, Zanchetti, A, Malacco, E, Mancia, G, Staessen, J, Fagard, R, Holman, R, Hansson, L, Kostis, J, Kanno, Y, Lueders, S, Matsuzaki, M, Poole-Wilson, P, Schrader, J, Rahimi, K, Anderson, C, Chapman, N, Collins, R, Macmahon, S, Neal, B, Rodgers, A, Whelton, P, Woodward, M, Agodoa L., Estacio R., Schrier R., Lubsen J., Chalmers J., Cutler J., Davis B., Wing L., Poulter N. R., Sever P., Remuzzi G., Ruggenenti P., Nissen S., Lindholm L. H., Fukui T., Ogihara T., Saruta T., Black H., Sleight P., Lievre M., Suzuki H., Fox K., Lisheng L., Ohkubo T., Imai Y., Yusuf S., Bulpitt C. J., Lewis E., Brown M., Palmer C., Wang J., Pepine C., Ishii M., Yui Y., Kuramoto K., Pfeff Er M., Asselbergs F. W., Van Gilst W. H., Byington B., Pitt B., Brenner B., Remme W. J., De Zeeuw D., Rahman M., Viberti G., Teo K., Zanchetti A., Malacco E., Mancia G., Staessen J., Fagard R., Holman R., Hansson L., Kostis J., Kanno Y., Lueders S., Matsuzaki M., Poole-Wilson P., Schrader J., Rahimi K., Anderson C., Chapman N., Collins R., MacMahon S., Neal B., Rodgers A., Whelton P., and Woodward M.
- Abstract
Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (<25 kg/m2, 25 to <30 kg/m2, and ≥30 kg/m2) or a continuous variable. Findings Analyses were based on 135 715 individuals from 22 trials who had 14 353 major cardiovascular events. None of the six primary comparisons showed evidence that protection varied by drug class across the three BMI groups (all p for trend >0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.
- Published
- 2015
28. Influence of Ethanol on Oxycodone-induced Respiratory Depression A Dose-escalating Study in Young and Elderly Individuals
- Author
-
Schrier, R. van der, Roozekrans, M., Olofsen, E., Aarts, L., Velzen, M. van, Jong, M. de, Dahan, A., and Niesters, M.
- Published
- 2017
29. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)
- Author
-
Rahimi, K, Canoy, D, Nazarzadeh, M, Salimi-Khorshidi, G, Woodward, M, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, N, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, B, Cutler, J, Devereaux, RB, Dwyer, D, Fagard, R, Fox, K, Fukui, T, Gupta, AJ, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Othisgihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Poulter, NR, Rakugi, H, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, Van Gilst, WH, Verdecchia, P, Wachtell, K, Yui, Y, Yusuf, S, Baigent, C, Collins, R, De Zeeuw, D, Neal, B, Perkovic, V, Rahman, M, Remme, WJ, Rodgers, A, Sundstrom, J, Turnbull, F, Foundation for Circulatory Health, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Staessen, Jan
- Subjects
medicine.medical_specialty ,Epidemiology ,Disease ,REGIMENS ,030204 cardiovascular system & hematology ,Research Support ,Phase (combat) ,03 medical and health sciences ,Medicine, General & Internal ,0302 clinical medicine ,General & Internal Medicine ,Diabetes mellitus ,Protocol ,medicine ,Journal Article ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Non-U.S. Gov't ,Stroke ,Antihypertensive Agents ,Randomized Controlled Trials as Topic ,RISK ,Protocol (science) ,Medicine(all) ,Science & Technology ,efficacy and safety of bp lowering treatment ,HYPERTENSION ,business.industry ,Research Support, Non-U.S. Gov't ,blood pressure ,General Medicine ,medicine.disease ,PROSPECTIVELY-DESIGNED OVERVIEWS ,MODEL ,Treatment Outcome ,MAJOR CARDIOVASCULAR EVENTS ,Blood pressure ,Patient level data ,meta-analyses ,Blood pressure lowering ,business ,Life Sciences & Biomedicine ,Blood Pressure Lowering Treatment Trialists’ Collaboration - Abstract
IntroductionPrevious research from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) and others has shown that pharmacological blood pressure (BP)- lowering substantially reduces the risk of major cardiovascular events, including ischaemic heart disease, heart failure and stroke. In this new phase, the aim is to conduct individual patient-level data (IPD) meta-analyses involving eligible BP-lowering randomised controlled trials (RCTs) to address uncertainties relating to efficacy and safety of BP-lowering treatment.Methods and analysisRCTs investigating the effect of pharmacological BP-lowering, with a minimum of 1000 patient-years of follow-up in each trial arm, are eligible. Our systematic review identified 100 potentially eligible trials. We requested their investigators/sponsors to contribute baseline, follow-up and outcomes data. As of June 2018, the collaboration has obtained data from 49 trials (n=315 046 participants), with additional data currently in the process of being transferred from four RCTs (n=34 642 participants). In addition, data harmonisation has commenced. Scientific activities of the collaboration are overseen by the Steering Committee with input from all collaborators. Detailed protocols for individual meta-analyses will be developed and registered on public platforms.Ethics and disseminationEthics approval has been obtained for this new and extended phase of the BPLTTC, the largest collaboration of de-identified IPD from RCTs. It offers an efficient and ethical manner of re-purposing existing data to answer clinically important questions relating to BP treatment as well as methodological questions relating to IPD meta-analyses. Among the immediate impacts will include reliable quantification of effects of treatment modifiers, such as baseline BP, age and prior disease, on both vascular and non-vascular outcomes. Analyses will further assess the impact of BP-lowering on important, but less well understood, outcomes, such as new-onset diabetes and renal disease. Findings will be published in peer-reviewed medical journals on behalf of the collaboration.
- Published
- 2019
30. Efficacia e tollerabilità della terapia con tolvaptan in pazienti con sindrome da inappropriata secrezione di ADH
- Author
-
Verbalis, J. G., Adler, S., Schrier, R. W., Berl, T., Zhao, Q., Czerwiec, F. S., and Arvat, Emanuela
- Published
- 2011
- Full Text
- View/download PDF
31. Sodium and Water Excretion in Patients with Congestive Heart Failure and Cirrhosis
- Author
-
Bichet, Daniel, Schrier, R. W., and Messerli, Franz H., editor
- Published
- 1984
- Full Text
- View/download PDF
32. Hypocalciuric Effect of Lithium in Man
- Author
-
Miller, P. D., Dubovsky, S. L., Schrier, R. W., McDonald, K. M., Arnaud, C., Massry, Shaul G., editor, and Ritz, Eberhard, editor
- Published
- 1977
- Full Text
- View/download PDF
33. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
- Author
-
Agodoa, L, Anderson, C, Asselbergs, FW, Baigent, C, Black, H, Brenner, B, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, de Zeeuw, D, Dens, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Hansson, L, Holman, R, Hunsicker, L, Imai, Y, Ishii, M, Kanno, Y, Kostis, J, Kuramoto, K, Lewis, E, Lievre, M, Lindholm, LH, Liu, L, Lubsen, J, Lueders, S, MacMahon, S, Malacco, E, Mancia, G, Matsuzaki, M, Neal, B, Nissen, S, Ohkubo, T, Ogihara, T, Pepine, C, Pfeffer, M, Pitt, B, Poole-Wilson, P, Poulter, N, Rahman, M, Remme, W, Remuzzi, G, Rodgers, A, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, J, Suzuki, H, Teo, K, van Gilst, WH, Viberti, G, Wang, J, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Barzi, F, Heritier, S, Li, N, Ninomiya, T, Perkovic, V, Turnbull, F, Woodward, M, Wilson, K, Kearney, ACP, Gallagher, M, Cass, A, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Cardiology, Clinical Research Unit, Pathology, Graduate School, ACS - Heart failure & arrhythmias, and Amsterdam Reproduction & Development (AR&D)
- Subjects
medicine.medical_specialty ,Hemodynamics ,Renal function ,CONVERTING ENZYME-INHIBITOR ,PLACEBO-CONTROLLED TRIAL ,CALCIUM-ANTAGONIST ,DOUBLE-BLIND ,HYPERTENSIVE PATIENTS ,RISK-FACTOR ,Internal medicine ,medicine ,Myocardial infarction ,Intensive care medicine ,PUBLICATION BIAS ,biology ,business.industry ,Research ,Angiotensin-converting enzyme ,General Medicine ,medicine.disease ,RENAL OUTCOMES ,Blood pressure ,ATHEROSCLEROSIS ,Heart failure ,Cardiology ,Aortic pressure ,biology.protein ,CORONARY-ARTERY-DISEASE ,business ,Kidney disease - Abstract
Objective To define the cardiovascular effects of lowering blood pressure in people with chronic kidney disease.Design Collaborative prospective meta-analysis of randomised trials.Data sources and eligibility Participating randomised trials of drugs to lower blood pressure compared with placebo or each other or that compare different blood pressure targets, with at least 1000 patient years of follow-up per arm.Main outcome measures Major cardiovascular events (stroke, myocardial infarction, heart failure, or cardiovascular death) in composite and individually and all cause death.Participants 26 trials (152 290 participants), including 30 295 individuals with reduced estimated glomerular filtration rate (eGFR), which was defined as eGFRData extraction Individual participant data were available for 23 trials, with summary data from another three. Meta-analysis according to baseline kidney function was performed. Pooled hazard ratios per 5 mm Hg lower blood pressure were estimated with a random effects model.Results Compared with placebo, blood pressure lowering regimens reduced the risk of major cardiovascular events by about a sixth per 5 mm Hg reduction in systolic blood pressure in individuals with (hazard ratio 0.83, 95% confidence interval 0.76 to 0.90) and without reduced eGFR (0.83, 0.79 to 0.88), with no evidence for any difference in effect (P=1.00 for homogeneity). The results were similar irrespective of whether blood pressure was reduced by regimens based on angiotensin converting enzyme inhibitors, calcium antagonists, or diuretics/beta blockers. There was no evidence that the effects of different drug classes on major cardiovascular events varied between patients with different eGFR (all P>0.60 for homogeneity).Conclusions Blood pressure lowering is an effective strategy for preventing cardiovascular events among people with moderately reduced eGFR. There is little evidence from these overviews to support the preferential choice of particular drug classes for the prevention of cardiovascular events in chronic kidney disease.
- Published
- 2016
34. Effect of Beta-Adrenergic Stimulation on Renin Release
- Author
-
Reid, I. A., Schrier, R. W., Earley, L. E., and Assaykeen, Tatiana A., editor
- Published
- 1972
- Full Text
- View/download PDF
35. Doxapram‐mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic–Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers
- Author
-
Roozekrans, M, primary, Olofsen, E, additional, van der Schrier, R, additional, Boom, M, additional, Mooren, R, additional, and Dahan, A, additional
- Published
- 2017
- Full Text
- View/download PDF
36. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index : A meta-analysis of randomised trials
- Author
-
Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Epidemiology and Data Science, Graduate School, APH - Methodology, and APH - Personalized Medicine
- Subjects
medicine.medical_specialty ,DISEASE ,Body Mass Index ,EVENTS ,Internal medicine ,medicine ,Humans ,Obesity ,Stroke ,Antihypertensive Agents ,METABOLIC SYNDROME ,Randomized Controlled Trials as Topic ,Medicine(all) ,business.industry ,MORTALITY ,Hazard ratio ,General Medicine ,medicine.disease ,PREVENTION ,EUROPEAN-SOCIETY ,PROSPECTIVELY-DESIGNED OVERVIEWS ,REDUCTION ,Blood pressure ,Cardiovascular Diseases ,Heart failure ,Meta-analysis ,Hypertension ,Physical therapy ,Metabolic syndrome ,business ,Body mass index ,Risk Reduction Behavior - Abstract
Summary Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m2 higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. Interpretation We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. Funding None.
- Published
- 2015
37. A Cellular Mechanism for Cyclosporine A-Induced Nephrotoxicity
- Author
-
Meyer-Lehnert, H., Schrier, R. W., Andreucci, Vittorio E., editor, and Dal Canton, Antonio, editor
- Published
- 1989
- Full Text
- View/download PDF
38. Portable lactate analyzer for measuring lactate in cerebrospinal fluid (CSF) and plasma - Method-comparison evaluations
- Author
-
de Almeida, SM, Marquie-Beck, J, Bhatt, A, Letendre, S, McCutchan, JA, Ellis, RJ, Heaton, RK, Grant, I, Atkinson, JH, Marcotte, TD, Sherman, M, Best, B, Schrier, R, Alexander, T, Rosario, D, Woods, SP, Cherner, M, Moore, DJ, Dawson, M, Fennema-Notestine, C, Jernigan, T, Buchsbaum, MS, Hesselink, J, Archibald, SL, Brown, G, Buxton, R, Dale, A, Liu, T, Masliah, E, Achim, C, Everall, I, Smith, DM, Richman, D, Lipton, S, Gamst, AC, Cushman, C, Abramson, I, Vaida, F, Deutsch, R, Umlauf, A, and Kao, C
- Abstract
Increased plasma lactate levels can indicate the presence of metabolic disorders in HIV infected individuals. Objective: To determine whether a portable analyzer is valid for measuring cerebrospinal fluid (CSF) and plasma lactate levels in HIV infected individuals. Method: CSF and plasma were collected from 178 subjects. Samples tested by the Accutrend® portable analyzer were compared to those tested by a reference device (SYNCHRON LX® 20). Results: The portable analyzer had in plasma sensitivity of 0.95 and specificity 0.87. For CSF the specificity was 0.95; the sensitivity 0.33; the negative predictive value was 95% and the positive predictive value 33%. Conclusions: These findings support the validity of the portable analyzer in measuring lactate concentrations in CSF that fall within the normal range. The relatively poor positive predictive value indicates that a result above the reference range may represent a "false positive test", and should be confirmed by the reference device before concluding abnormality.
- Published
- 2014
39. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials
- Author
-
Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., Woodward, M., Cardiologie, Circulatory Health, Agodoa, L., Estacio, R., Schrier, R., Lubsen, J., Chalmers, J., Cutler, J., Davis, B., Wing, L., Poulter, N. R., Sever, P., Remuzzi, G., Ruggenenti, P., Nissen, S., Lindholm, L. H., Fukui, T., Ogihara, T., Saruta, T., Black, H., Sleight, P., Lievre, M., Suzuki, H., Fox, K., Lisheng, L., Ohkubo, T., Imai, Y., Yusuf, S., Bulpitt, C. J., Lewis, E., Brown, M., Palmer, C., Wang, J., Pepine, C., Ishii, M., Yui, Y., Kuramoto, K., Pfeff Er, M., Asselbergs, F. W., Van Gilst, W. H., Byington, B., Pitt, B., Brenner, B., Remme, W. J., De Zeeuw, D., Rahman, M., Viberti, G., Teo, K., Zanchetti, A., Malacco, E., Mancia, G., Staessen, J., Fagard, R., Holman, R., Hansson, L., Kostis, J., Kanno, Y., Lueders, S., Matsuzaki, M., Poole-Wilson, P., Schrader, J., Rahimi, K., Anderson, C., Chapman, N., Collins, R., MacMahon, S., Neal, B., Rodgers, A., Whelton, P., and Woodward, M.
- Published
- 2015
40. Cellular mechanism of ischemic acute renal failure: Role of Ca2+ and calcium entry blockers
- Author
-
Schrier, R. W. and Hensen, J.
- Published
- 1988
- Full Text
- View/download PDF
41. Variation of proximal tubular reabsorptive capacity by volume expansion and aortic constriction during constancy of peritubular capillary protein concentration in rat kidney
- Author
-
Holzgreve, H., Schrier, R. W., Müller, M., Simmen, D., and Stephan, R.
- Published
- 1975
- Full Text
- View/download PDF
42. Differentialdiagnose und Behandlung bei Hyponatriämie
- Author
-
Gross, P., Handelman, W., and Schrier, R. W.
- Published
- 1980
- Full Text
- View/download PDF
43. Hemodynamic factors in the pathogenesis of diabetic nephropathy
- Author
-
Schrier, R. W. and Holzgreve, H.
- Published
- 1988
- Full Text
- View/download PDF
44. Evaluation of peritubular capillary microperfusion method by morphological and functional studies
- Author
-
Holzgreve, H. and Schrier, R. W.
- Published
- 1975
- Full Text
- View/download PDF
45. Kering is een val voor bruinvis (interview met Okka Jansen)
- Author
-
Schrier, R. and Jansen, O.E.
- Subjects
Aquatic Ecology and Water Quality Management ,Aquatische Ecologie en Waterkwaliteitsbeheer - Published
- 2013
46. Expression of mannose binding lectin in HIV-1-infected brain: Implications for HIV-related neuronal damage and neuroaids
- Author
-
Singh, KK, Nathamu, S, Adame, A, Alire, TU, Dumaop, W, Gouaux, B, Moore, DJ, Masliah, E, Grant, I, Atkinson, JH, Ellis, RJ, McCutchan, JA, Marcotte, TD, Marquie-Beck, J, Sherman, M, Letendre, S, Capparelli, E, Schrier, R, Alexander, T, Rosario, RND, LeBlanc, S, Heaton, RK, Woods, SP, Cherner, M, Dawson, M, Jernigan, T, Fennema-Notestine, C, Archibald, SL, Hesselink, MAJ, Annese, J, Taylor, MJ, Achim, C, Everall, I, Richman, D, Smith, DM, Lipton, S, von Jaeger, R, Gamst, AC, Abramson, I, Vaida, F, Deutsch, R, Umlauf, A, and Wolfson, T
- Subjects
chemical and pharmacologic phenomena ,bacterial infections and mycoses - Abstract
Mannose binding lectin (MBL) activates complement pathway that leads to pathogen opsonization and phagocytosis. MBL deficiency is linked to HIV transmission and disease progression. We sought to determine the role of MBL in HIV encephalitis (HIVE) by evaluating its presence and distribution in the HIV-1-infected brain and by assessing its association with monocyte chemoattractant protein-1 (MCP-1) expression. This retrospective study utilized archived post-mortem brain tissues obtained from 35 individuals enrolled in a longitudinal study as part of the California NeuroAIDS Tissue Network. MBL, MCP-1 and brain cell markers in post-mortem brain tissues with or without HIVE were evaluated using immunocytochemistry, immunofluorescence, confocal microscopy, and western blots. MBL was expressed in neurons, astrocytes, microglia, and oligodendrocytes of the frontal cortex of the HIV-1-infected brain. Overall, there were 30% to 40% more MBL-positive brain cells in HIVE vs non-HIVE cases (P = 0.01, paired t-test). Specifically, there was an increased MBL expression in the neuronal axons of HIVE cases. Also, western blots showed 3- to 4-fold higher levels of 78 kD MBL trimers in HIVE vs non-HIVE cases. This MBL-HIVE link was further confirmed by MBL associated higher MCP-1 expression in HIVE vs non-HIVE cases. HIV negative healthy individuals and normal or the gp120 transgenic mice did not show any differential MBL expression. Increased MBL expression in the major brain cell types, specifically in the neuronal axons of HIVE brain, and MBL associated higher MCP-1 expression in HIVE suggest that MBL could cause neuroinflammation and neuronal injury through MBL complement activation pathway. © 2011 Singh et al, publisher and licensee Dove Medical Press Ltd.
- Published
- 2011
47. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system
- Author
-
Agodoa, L, Anderson, C, Asseibergs, F, Baigent, C, Black, H, Brenner, B, Brown, M, Bulpitt, C, Byington, R, Chalmers, J, Collins, R, Cutler, J, Dahlof, B, Davis, B, de Zeeuw, D, Dens, J, Estacio, R, Fagard, Robert, Fox, K, Fukui, T, Hansson, L, Holman, R, Hunsicker, L, Imai, Y, Ishii, M, Kanno, Y, Kostis, J, Kuramoto, K, Lewis, E, Lievre, M, Lindholm, LH, Liu-Huang, Li-chuan, Lubsen, J, Lueders, S, MacMahon, S, Malacco, E, Mancia, G, Matsuzaki, M, Neal, B, Nissen, S, Ohkubo, T, Ogihara, T, Pepine, C, Pfeffer, M, Pitt, B, Poole-Wilson, P, Rahman, M, Remme, W, Remuzzi, G, Rodgers, A, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, Jan A, Teo, K, Viberti, G, Wang, J, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Swedberg, K, Kjekshus, J, Algert, C, Perkovic, V, Turnbull, F, Woodward, M, and Groningen Kidney Center (GKC)
- Subjects
coronary-artery-disease ,Physiology ,CONVERTING-ENZYME-INHIBITORS ,converting-enzyme-inhibitors ,Placebo-controlled study ,heart failure ,Angiotensin-Converting Enzyme Inhibitors ,high-risk patients ,030204 cardiovascular system & hematology ,PLACEBO-CONTROLLED TRIAL ,Renin-Angiotensin System ,Coronary artery disease ,0302 clinical medicine ,placebo-controlled trial ,HYPERTENSIVE PATIENTS ,030212 general & internal medicine ,prospectively-designed overviews ,Stroke ,Randomized Controlled Trials as Topic ,major cardiovascular events ,blood pressure ,stroke ,CHRONIC HEART-FAILURE ,3. Good health ,Cardiovascular Diseases ,randomized controlled-trial ,Cardiology ,ventricular systolic function ,Cardiology and Cardiovascular Medicine ,meta-regression analyses ,RECEPTOR BLOCKERS ,medicine.medical_specialty ,Placebo ,Sensitivity and Specificity ,03 medical and health sciences ,VENTRICULAR SYSTOLIC FUNCTION ,Internal medicine ,Renin–angiotensin system ,Internal Medicine ,medicine ,Humans ,CARDIOVASCULAR MORBIDITY ,cardiovascular diseases ,coronary heart disease ,HIGH-RISK PATIENTS ,lipid-lowering treatment ,business.industry ,medicine.disease ,RANDOMIZED-TRIAL ,chronic heart-failure ,Blood pressure ,MYOCARDIAL-INFARCTION ,meta-analyses ,Relative risk ,Heart failure ,business ,Angiotensin II Type 1 Receptor Blockers - Abstract
Objectives To evaluate the blood pressure-dependent and independent effects of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on major cardiovascular events.Methods Using data from 26 large-scale trials comparing an ACEI or an ARB with placebo or another drug class, meta-regression analyses were conducted in which treatment-specific relative risks for major cause-specific outcomes [stroke, major coronary heart disease (CHD) events and heart failure] were regressed against follow-up blood pressure differences.Results From a total of 146 838 individuals with high blood pressure or an elevated risk of cardiovascular disease, 22 666 major cardiovascular events were documented during follow-up. The analyses showed comparable blood pressure-dependent reductions in risk with ACEI and ARB (P > 0.3 for all three outcomes). The analyses also showed that ACEI produced a blood pressure-independent reduction in the relative risk of CHD of approximately 9% (95% confidence interval 3-14%). No similar effect was detected for ARB, and there was some evidence of a difference between ACEI and ARB in this regard (P =0.002). For both stroke and heart failure there was no evidence of any blood pressure-independent effects of either ACEI or ARB.Conclusion There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure. For ACEI, but not ARB, there is evidence of blood pressure-independent effects on the risk of major coronary disease events.
- Published
- 2007
48. Disorders of Water Metabolism
- Author
-
Schrier, R. W., primary and Szatalowicz, V. L., additional
- Full Text
- View/download PDF
49. Humoral, Neural and Hemodynamic Influences on Renal Water Excretion1
- Author
-
Schrier, R. W., primary, Berl, T., additional, Anderson, R. J., additional, and McDonald, K. M., additional
- Full Text
- View/download PDF
50. Sepsis and Acute Renal Failure
- Author
-
Schrier, R. W., primary, Zolty, E., additional, and Wang, W., additional
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.